Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is projected to experience significant revenue growth, with product sales expected to rise from $1.73 billion in 2025 to $2.15 billion in 2026, supported by a robust pipeline of 35 mRNA development candidates addressing various therapeutic areas. The company has also demonstrated improvements in manufacturing efficiency, which are anticipated to expand gross margins from 30% in 2023 back to 50% by 2025, enhancing overall financial performance. Additionally, a recently secured $1.5 billion debt deal is expected to bolster Moderna's balance sheet, providing flexibility to navigate uncertainties and capitalize on future growth opportunities.

Bears say

The financial analysis reveals a negative outlook on Moderna's stock due to several factors impacting revenue growth potential. The projected decline in COVID vaccine sales from $18 billion in 2022 to $6.7 billion in 2023, along with anticipated long-term revenue reductions related to COVID vaccines, highlight significant headwinds for the company. Additionally, challenges from competitive products in the respiratory vaccine space and slow progress in their development pipeline contribute to concerns over overall future profitability and revenue stability.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.